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The recent exciting advances in our understanding of the regulation of the energy sensor AMP-activated pro-
tein kinase (AMPK), together with renewed appreciation of its importance in maintaining cellular function,
brought together leading scientists at a recent FASEB-sponsoredmeeting inSeptember 2014.Here,we report
some of the highlights of this conference.Introduction
The AMP-activated protein kinase (AMPK) is a sensor of cellular
energy status that directs metabolic adaptation to support
cellular growth and survival. AMPK is activated by changes in
the cellular AMP:ATP and ADP:ATP ratios and functions to
restore energy homeostasis by switching off biosynthetic path-
ways consuming ATP while switching on catabolic pathways
that produce ATP. Over the last 20 years, the AMPK field has
grown enormously, from a few dozen papers to over 1,000 pub-
lished per year. The field has grown from a group of 10–12 inves-
tigators interested in the biological actions of AMPK in the 1990s
to literally hundreds of investigators worldwide studying this
pathway. Indeed, recent research has expanded the paradigm
of AMPK as a metabolic sensor and to the more global concept
that AMPK has broad effects on cellular function, providing syn-
ergy between research in energy metabolism and other areas of
science such as cancer and immunology. The downstream ac-
tions of AMPK regulate numerous steps in cellular metabolism,
cell growth, organelle regulation including mitochondrial biogen-
esis, autophagy, oxidative stress, and cell polarity. As a result,
AMPK is an attractive target for the development of drugs aimed
at preventing and/or treating metabolic diseases and cancer.
Recent breakthroughs in the field of AMPK research were pre-
sented on the occasion of a FASEB Scientific Research Confer-
ence titled ‘‘AMPK: Biological Action and Therapeutic Perspec-
tives.’’ This was the eighth international conference in the series
(the original conference was held in Boston in 2000, organized
by Dr. Neil Ruderman, Boston Medical Center/Boston University
School of Medicine), with the last five meetings organized on the
behalf of FASEB Scientific Research Conference. This last con-
ference was held from September 28 to October 3, 2014, in the
picturesque town of Barga, just outside of Lucca, Italy. In a beau-
tiful location providing an inspiring and intimate setting, scientists
from 22 different countries gathered together to discuss basic
AMPK biology and provide future direction for AMPK therapy in
disease-focused research (Figure 1). More than 50 excellent
and varied talks, including studies of basic and clinical relevance,
addressed recent breakthroughs in the expanding field of AMPK.
It would not be possible to provide a comprehensive report of allof the talks, and so in this short report we have selected some of
the highlights that arose during the meeting.
Deconstructing the Complexity of AMPK Regulation
AMPK is a heterotrimeric complex composed of one catalytic a
subunit comprising a typical Ser/Thr kinase domain, one scaffold
b subunit containing a carbohydrate binding module (CBM) and
one regulatory g subunit containing four cystathionine-b-syn-
thase (CBS) domains, that serve to bind adenine nucleotides.
Themechanism of AMPK activation involves two steps, a revers-
ible phosphorylation at a conserved residue (Thr172 in the rat
catalytic subunit sequence) within the activation loop in the a
subunit, and a stimulatory allosteric effect upon binding of
AMP within the CBS domains of the g subunit. In addition,
AMP and ADP binding regulates AMPK by promoting Thr172
phosphorylation by the upstream kinases, liver kinase B1
(LKB1), and Ca2+/calmodulin-dependent protein kinase b
(CaMKKb), and by protecting Thr172 from dephosphorylation
by phosphatases. All these effects of AMP are antagonized by
binding of ATP, providing a very sensitive mechanism for the
activation of AMPK in conditions of cellular energy stress. Gra-
hame Hardie (University of Dundee) reviewed the current knowl-
edge of the ‘‘canonical’’ mechanisms for the regulation of AMPK
by energy stress and presented alternative ‘‘noncanonical’’
mechanisms, including activation by CaMKKb, and repression
by Akt and other kinases. Recent studies suggested that phos-
phorylation of a serine/threonine-rich insert (ST loop) within the
a subunit inhibits subsequent phosphorylation of Thr172 by
blocking access of upstream kinases LKB1 or CaMKKb to
Thr172 and represents antagonistic mechanisms to downregu-
late AMPK signaling (Hawley et al., 2014). Yvonne Oligschla¨ger
(Maastricht University) provided new insight into the regulation
of glycogen binding to AMPK through autophosphorylation at
Thr148 within the CBM of the b subunit. Thr148 phosphorylation
was found to inhibit glycogen localization of AMPK, thus
affecting cellular glycogen turnover (Oligschlaeger et al., 2015).
Shengcai Lin (Xiamen University) presented a novel mechanism
by which AMP regulates AMPK activation. In response to starva-
tion or exogenous AMP, AMP binding triggers the interactionCell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc. 799
Figure 1. Attendees of the FASEB Science Research Conference, AMPK: Biological Action and Therapeutic Perspectives, Held in Lucca,
Italy, September 28–October 3, 2014
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also binds to LKB1. Of note, ADP has no effect on the AXIN-
based complex formation. The formation of the AXIN-AMPK-
LKB1 complex facilitates the phosphorylation of AMPK by
LKB1 and causes AMPK activation. In follow-up studies, it was
demonstrated that this mechanism occurs at the late endo-
some/lysosome surface and is dependent on the v-ATPase-Ra-
gulator complex (Zhang et al., 2014). Interestingly, v-ATPase and
Ragulator proteins are known to be important components for
recruiting and activating mechanistic target of rapamycin com-
plex 1 (mTORC1) to the lysosome under nutrient-rich conditions.
These results suggest a general role of late endosome/lysosome
in sensing of nutrient by both the AMPK and the mTORC1
signaling pathways, thereby providing a switch between catab-
olism and anabolism. The functional consequence for AMPK
recruitment at the late endosomal/lysosomal protein complex
v-ATPase/Ragulator on the inverse relationship between
AMPK and mTORC1 signaling pathways were discussed. To
add a further layer of complexity in the regulation of AMPK acti-
vation, Bruce Kemp (St. Vincent Institute of Medical Research
and University of Melbourne) provided evidence for activation
of naive AMPK independently of Thr172 phosphorylation (Scott
et al., 2014). The small-molecule AMPK activator A769662 was
found to activate AMPK not phosphorylated on Thr172. In
contrast to adenine nucleotides, A-769662 does not bind the g800 Cell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc.subunit but requires the b subunit and its autophosphorylation
at Ser108 within the CBM to allosterically activate AMPK. Inter-
estingly, a synergistic AMPK activation was found with the com-
bination of A-769662 and AMP, independently of both a subunit
Thr172 and b subunit Ser108 phosphorylation (Scott et al., 2014).
These findings raise the exciting possibility that combinatorial
strategies based on AMP and small molecule activators
may be relevant for AMPK-based therapy in disease-focused
research, and further studies are eagerly anticipated.
Over the last few years, knowledge gained through the avail-
ability of mammalian AMPK crystal structures has fundamentally
advanced the understanding on the mechanism by which
adenine nucleotides regulate AMPK activity. Structural informa-
tion on AMPK complexesmay also help for the design of specific
small-molecule activators for clinical applications. Crystal
structures of AMPK bound with AMP revealed that only three of
the four potential nucleotide-binding sites within the g subunit
contribute to nucleotide regulation. Binding studies using
AMPK in solution revealed that two sites (sites 1 and 3) are
competitively bound by either AMP, ADP, or ATP. In contrast,
nucleotide bound as site 4 was not exchangeable. Site 2 is unoc-
cupied, possibly because this site lacks an aspartate residue
found in the other sites that interacts with the ribose ring of the
bound nucleotide. Binding of AMP at site 1 was assigned to the
effect on allosteric activation, whereas binding of AMP or ADP
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tant breakthrough came from the crystal structure of AMPK reg-
ulatory core fragment and the kinase domain of the a subunit,
providing insights on the conformational changes induced by
binding of adenine nucleotides and the dynamics of communica-
tion among the different subunits. Flexible components from the
a subunit (a-RIM/a-hook) interact with the exchangeable nucleo-
tide-binding site 3 on the g subunit and favor a conformation
change in which Thr172 interacts with the C-terminal regions of
the a- and b subunits, offering a protection against dephosphor-
ylation. Steve Gamblin (The Francis Crick Institute) presented re-
sults based on structural studies for full-length human AMPK
a2b1g1 heterotrimer in complex with the small molecule activa-
tors 991 and A-769662 (Xiao et al., 2013). The molecular mecha-
nisms for these two compounds are very similar, as they bind to
the same site localized at the interface of the kinase domain and
the CBMof the b subunit. Binding of 991 and A-769662 stabilizes
the interaction between theCBMand the kinase domain,which in
turn has a stabilizing effect on the interaction of the activation
loop structure, enhancing the protection against dephosphoryla-
tion of T172. In addition to X-ray crystallography data, Matt
Sanders (The Francis Crick Institute) presented results from bio-
physicalmethods (circular dichroismandbiolayer interference) to
compare binding of small molecule activators to AMPK com-
plexes, showing that compound 991 binds significantly tighter
to a2/a1b1g1 and a1b2g1 heterotrimers than A-769662. Ravi
Kurumbail (Pfizer) described similar molecular mechanisms
based on the crystal structure of full-length a2b1g1 heterotrimer
bound with a series of ligands related to A-769662 (Calabrese
et al., 2014). A-769662 and its analog bind to a novel allosteric
pocket between the CBM and the kinase domain and mediate
their effects primarily through decreasing Km for the substrate
peptide. In contrast, a different molecular mechanism has been
reported for AMP, which regulates AMPK by increasing the
Vmax of phosphorylation reaction. Uwe Schlattner (INSERM and
University Grenoble Alpes) presented a complementary
approach to structural studies to gain insight into the role of
CBS domains for allosteric AMPK activation. He developed an
AMPK FRET sensor based on the nucleotide-induced conforma-
tional switch model. This molecular sensor allows a direct and
real-time readout of the AMPK conformational change upon
ligand binding and may be exploited for various analytical
applications as well as versatile tools for screening and in vivo
applications.
Peripheral and Central Regulation of Energy Balance by
AMPK
AlthoughAMPKwasoriginally identified as a sensor of cellular en-
ergy status by coordinating anabolic and catabolic pathways to
balance nutrient supply with energy demand, it is now clear that
it also participates in the control of whole-body energy homeosta-
sis by integrating signals from the cellular environment andwhole
organism. There are a number of hormones involved in the regula-
tion of whole-body energy balance which alter AMPK activation.
Takashi Kadowaki (University of Tokyo) discussed the role of
AMPK in mediating the antidiabetic and antiatherogenic actions
of adiponectin, a hormone that is derived from adipose tissue
and is reduced in obesity-linked diseases. Adiponectin exerts its
effects by binding to the adiponectin receptors, AdipoR1 andAdi-poR2, which mediate increased AMPK and peroxisome prolif-
erator-activated receptor (PPAR)-a activities to regulate normal
glucose and lipid metabolism and insulin sensitivity. He reported
the identification of an orally active small-molecule AdipoR1/R2
agonist, termedAdipoRon,with very similar effects to adiponectin
in muscle and liver, with activation of AMPK and PPAR-a path-
ways and ameliorated insulin resistance and glucose intolerance
in obese diabetic mice on a high-fat diet (Okada-Iwabu et al.,
2013). Another layer of signal integration for the regulation of
whole-body energy balance happens at the level of hypothalamic
AMPK that acts by controlling both feeding and energy expendi-
ture. Miguel Lo´pez (Universidade de Santiago de Compostella)
further emphasized the role of AMPK in the ventromedial nucleus
of the hypothalamus as a central integrator of peripheral signals
andmediator of the effects of thyroid hormones, bonemorphoge-
netic protein 8B (BMP8B), nicotine, and oestradiol on the regula-
tion of peripheral metabolism and particularly brown adipose tis-
sue thermogenesis (Martı´nez de Morentin et al., 2014).
Investigating Emerging AMPK Signaling Pathways
AMPK regulates awide array of physiological events and, consis-
tently, is expected to have a tremendous impact on survival,
growth, and development at the organismal level. In addition,
impairment of the metabolic control of AMPK has been associ-
ated with the pathological context as well as many prevalent
human diseases including type 2 diabetes, insulin resistance,
cardiovascular diseases, and cancer. In order to explore more
deeply the various signaling pathway controlled by AMPK,
many groups have generated and analyzed various animal
models, ranging from rodents to the worm C. elegans. Pascal
Froment (INRA) talked about the role of AMPK inmale and female
reproduction.Malemice deficient in AMPKa1 showadecrease in
fertility due to structural abnormalities and alterations in the
motility of spermatozoa. Results from mice deficient in AMPKa1
in theSertoli cells established the importanceofAMPKonSertoli-
germ cell interactions and shaping of the sperm head. Deletion of
AMPKa1 in the oocyte also revealed a role for AMPK on oocyte
quality and oocyte/somatic cell communication (Bertoldo et al.,
2015). RichardRoy (McGill University) usedC. elegans to demon-
strate how AMPK coordinates the initiation of germline stem
cell division with environmental conditions. During periods of
nutrient/energy stress, AMPK is required to buffer adverse epige-
netic processes in these cells that ultimately cause reproductive
defects in subsequent unstressed generations.
Ian Salt (University of Glasgow) focused on the role of AMPK in
adipose tissue, influencing not only metabolism in adipocytes
but also acting to suppress proinflammatory signaling pathways.
He also discussed the importance of perivascular adipose tissue
(PVAT) in the pathophysiology of cardiovascular disease and
how dysregulation of AMPK in PVAT can influence vascular
function in obesity. In the same vein, Neil Ruderman (Boston
University Medical Center) described diminished AMPK activity
in multiple adipose tissue depots from insulin-resistant patients.
This is associated with oxidative stress, increased expression of
inflammatory cytokines, and decreased expression oxidative
phosphorylation genes in visceral fat. By contrast, the marked
increase in insulin sensitivity observed post-bariatric surgery
is accompanied by a significant increase in AMPK activity and
decreased oxidative stress in subcutaneous fat.Cell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc. 801
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ronmental cues. Mark Evans (University of Edinburgh) provided
genetic evidence for the contribution of AMPK to ventilatory ad-
justments during hypoxia in thatmice lackingAMPKexhibit hypo-
ventilation and apneas rather than hyperventilation. Thus AMPK
signaling links oxygen to energy supply at the whole-body level.
Re´mi Mounier (CNRS and Universite´ Claude Bernard Lyon1)
spoke about the regulation of stemcell fate during postnatal skel-
etal muscle regeneration. In response to muscle injury, muscle
stemcells (alsocalledsatellite cells) becomeactivatedand trigger
cellular reprogramming that results in enhanced proliferation,
differentiation, and/or self-renewal. By using mice deleted of
AMPKa1 in satellite cells, he showed that AMPK orchestrates
muscle stem cell fate by promoting metabolic reprogramming.
AMPK in Cancer: Friend or Foe?
More than 10 years ago, the discovery of the tumor suppressor
LKB1 as an upstream kinase of AMPK established a direct
connection between the regulation of energy metabolism and
cancer. However, accumulated data indicate that the functional
role of AMPK in cancer initiation and progression is much more
complex than expected. On one hand, AMPKcanmediate the tu-
mor suppressive signaling of LKB1 and is antitumorigenic; on the
other hand, AMPK is required for cancer cell survival undermeta-
bolic stress such as hypoxia and glucose deprivation and is pro-
tumorigenic. Thus, depending on the context, AMPK has a dual
role in carcinogenesis. Almut Schulze (Universitat Wu¨rzburg) re-
minded the participants that cancer cells undergo unique meta-
bolic reprogrammingduring transformation, andmanyoncogenic
signaling pathways directly regulate the activity of metabolic pro-
cesses to support unrestrained cell growth (Lewis et al., 2015).
Rosa Sen˜aris (Universidade de Santiago de Compostella) dis-
cussed the involvement of AMPK in the initiation and progression
of astrocytic tumors. She demonstrated that AMPK is found
constitutively activated in astrocytes expressing oncogenic
HRasV12 and help to coordinately support high cell division rates
by increasing extracellular lipid internalisation and reducing en-
ergy expenditure through the inhibition of de novo fatty acid syn-
thesis (Rı´os et al., 2014). Conversely, Tracey Rouault (NIH) pro-
vided an example in which AMPK acts as a tumor suppressor in
hereditary renal cancer caused by fumarate hydratase (FH) defi-
ciency. Reduced AMPK activity contributes to the oncogenic
growth of FH-deficient cells by promoting lipid synthesis and
anabolic reactions (Tonget al., 2011). Along thesame line,Russell
Jones (McGill University) demonstrated that AMPK can function
as a tumor suppressor in Myc-dependent lymphoma. Disruption
of AMPKsignaling promotesmetabolic reprogramming of cancer
cells with stabilization of the hypoxia-inducible factor-1a (HIF-1a)
to drive theWarburg effect. In this context, hepresentedevidence
supporting a role for AMPK in the control of mitochondrial
OXPHOS and ROS production. Dave Carling (MRC Clinical Sci-
ences Centre) discussed the role of AMPK cascade in prostate
cancer progression and presented evidence that activation of
AMPK in prostate cancer cells increases cell migration.
Annapoorni Rangarajan (Indian Institute of Science) presented
a novel role for AMPK in the acquisition of anoikis resistance, a
hallmark of solid tumors. By phosphorylating the antiapoptotic
protein PEA15, AMPK contribute to the anchorage-independent
growth of breast cancer cells (Hindupur et al., 2014). She evoked802 Cell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc.the exciting possibility that targeting theAMPK-PEA15 axismight
prevent breast cancer dissemination and metastasis. Masahisa
Jinushi (Hokkaido University) is interested in molecular mecha-
nisms by which macrophage-mediated phagocytosis of tumor
cells and regulates tumor immunosurveillance. He described
the participation of AMPKa1 with T cell immunoglobulin- and
mucin domain-containing molecule-4 (TIM-4) in the activation
of autophagic processes, which are critical for degrading in-
gested tumors and their associated antigens (Baghdadi et al.,
2013). These results indicate that targeting the TIM-4-AMPKa1
interactionmay constitute a unique strategy for augmenting anti-
tumor immunity and improving cancer chemotherapy.
Novel Regulatory Mechanisms in Cardiac and Skeletal
Muscle Metabolism
Over the past decade, AMPK has emerged as a key player in
the regulation of myocardial metabolism in response to ischemia,
pressure overload, and heart failure. Lawrence Young (Yale)
discussed AMPK regulation of mitochondrial function after
ischemia/reperfusion.Healso spokeabout the therapeutic poten-
tial ofD-dopachrome tautomerase (DDT), anovel secretedprotein
from cardiomyocytes which has important autocrine/paracrine
actions, for preventing cardiac injury during ischemia (Qi et al.,
2014). Interestingly, the cardioprotective effect of DDT requires
downstream AMPK activation via a calcium-dependent, energy-
independent mechanism implicating CaMKKb as the primary up-
stream kinase. Beside this protective action during myocardial
ischemia, AMPK activation also limits the development of cardiac
myocyte hypertrophy and increases cardiomyocyte response to
insulin. LucBertrand (Universite´CatholiquedeLouvain)described
new molecular mechanisms and AMPK downstream targets
involved in its insulin-sensitizing and antihypertrophic actions.
Sandrine Horman (Universite´ Catholique de Louvain) presented
evidence that AMPKa1 plays a critical role in in cardiac fibro-
blast/myofibroblast biology, providing new perspectives and po-
tential therapeutic approaches that could counter the adverse left
ventricular remodeling of infarcted hearts (Noppe et al., 2014).
Erik Richter and Jorgen Wojtaszewski (both University of
Copenhagen) reminded us of the important role of AMPK in skel-
etal muscle metabolism in response to exercise, in terms of both
glucose uptake and fatty acid oxidation. Erik Richter explored
the relative role of AMPK and Ca2+ in increasing glucose uptake
during muscle contraction and demonstrated that both meta-
bolic activation of AMPK and Rac1-dependent rearrangement
of the actin cytoskeleton, but not Ca2+ released from the sarco-
plasmic reticulum, fully account for contraction-induced muscle
glucose transport (Jensen et al., 2014). Jorgen Wojtaszewski
highlighted the differences in the fiber type-specific expression
and regulation of AMPK during exercise in humans (Kristensen
et al., 2015). He also discussed the importance of AMPK in fatty
acid oxidation during exercise (Fentz et al., 2015) and provided
evidence to support that AMPK activation is sufficient to in-
crease skeletal muscle insulin sensitivity (Kjøbsted et al., 2014).
Toward New AMPK Activators and Therapeutic
Applications
Numerous investigators and major pharmaceutical companies
have identified AMPK as a potential target for pharmacologic
development in the fields of diabetes, obesity, ischemic heart
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tific discovery, pharmaceutical companies are developing spe-
cific, direct-acting AMPK agonists that are critically important
for preclinical translational studies and early-stage clinical inves-
tigation to progress. Mark Rider (de Duve Institute and Universite´
Catholique de Louvain) focused on the effect of the small mole-
cule AMPK activator 991 on glucose uptake in skeletal muscle
(Beiroa et al., 2014). Incubation of rat epitrochlearis muscle
dose-dependently increases activity of AMPK complexes con-
taining various combinations of a1, a2, b1, or b2 subunits. Impor-
tantly, this work revealed that compound 991 increases glucose
uptake in an AMPK-dependent manner. Je´roˆme Tamburini (In-
serm, CNRS, and Universite´ Paris Descartes) employed a novel
AMPK activator GSK621 as a therapeutic agent in acute myeloid
leukemia (AML). Rather unexpectedly, mTORC1 activity corre-
lated with the degree of GSK621-induced cytotoxicity and de-
fines a mechanism of synthetic lethality with AMPK activation
(Sujobert et al., 2015). It is noteworthy that GSK621 has no effect
onnormalCD34+hematopoietic progenitor cells, adding support
for thedevelopment ofAMPKactivators aspromising therapeutic
molecules in AML. Benoit Viollet (Inserm, CNRS, and Universite´
Paris Descartes) defined the AMPK-dependent and -indepen-
dent metabolic actions of indirect and direct AMPK activators
on hepatic metabolism. Using mice lacking expression of both
AMPKa1/a2 catalytic subunits in the liver, it was established
that AMPK is dispensable for metformin- and AICAR-mediated
suppression of glucose production in primary hepatocytes
and the AICAR-induced decrease in glucose levels seen in vivo
(Foretz et al., 2010; Hasenour et al., 2014). In contrast,
these drugs, as well as the small-molecule AMPK activators
A-769662 and compound-13, are ineffective in inhibiting lipogen-
esis in the absence of hepatic AMPK (Hunter et al., 2014). Angela
Woods (MRC Clinical Sciences Centre) presented data using a
new genetic model for determining the effect of activation of
AMPK in vivo. In the liver, expression of a mutant g1 subunit led
to increasedbasal activity of AMPK, but surprisingly did not lower
lipid levels onmice fed either a normal or high-fat diet. GregStein-
berg (McMaster University) looked at the functional effects of
metformin in combination with salicylate on hepatic metabolism.
The two drugs synergistically activate AMPK and greatly
enhanced the inhibition of lipogenesis in murine and human he-
patocytes (Ford et al., 2015). In addition, low-dose metformin
and salicylate cotreatment synergistically reduced fatty liver
and enhanced insulin sensitivity in mice fed a high-fat diet. These
results reinforce the view that combinatorial treatments would be
of value to enhance AMPK activation and help to reduce the con-
centration of individual drugs administrated to patients.
Integrating LKB1 and AMPK-Related Kinases in the
Regulation of Metabolism
LKB1 is amaster kinase that phosphorylates andactivatesAMPK
and also a family of 12 closely related protein kinases, including
SIK (salt-induced kinase), MARK (microtubule-affinity-regulating
kinase), and BRSK (brain-specific kinase). A currently debated
issue is the precise role of the AMPK and AMPK-related protein
kinases in mediating the downstream effects of LKB1 on meta-
bolism. In this context, Kei Sakamoto (Nestle´ Institute of Health
Sciences SA) talked about the critical contribution of SIK family
members in the LKB1-mediated suppression of hepatic gluco-neogenesis gene transcription by regulating downstream tran-
scription factors/coactivators (Patel et al., 2014). These findings
support a model where the LKB1-SIKs but not the LKB1-AMPK
pathway functions as a key gluconeogenic gatekeeper in the
liver. Robert Screaton (Children’s Hospital of Eastern Ontario
Research Institute) looked at the function of SIK2 in pancreatic
b cells and the control of glucose homeostasis. By the use of
mice deficient in SIK2 in adult b cells, it was found that SIK2 is
required for glucose-induced insulin secretion and is essential
for adaptive b cell functional compensation in models of hyper-
glycaemia (Sakamaki et al., 2014). SIK2 phosphorylates the cy-
clin-dependent kinase 5 activator 1 CDK5R1/p35 to trigger its
ubiquitylation by the E3 ligase PJA2, resulting in activation of cal-
cium signaling and insulin secretion. Of note, SIK2 has a specific
role in regulating insulin secretion, as silencing SIK1 or SIK3 had
no effect in this regard. Olga Go¨ransson (Lund University) also
highlighted the importance of SIK2 in the regulation of metabolic
processes. She focused on the molecular targets and functions
of SIK2 in adipocytes. Based on recent work, she showed data
from primary adipocytes demonstrating the role of SIK2 in
the regulation of GLUT4 levels and glucose uptake, potentially
through its action onCREB regulated transcriptional coactivators
(CRTCs) and histone deacetylase (HDAC) 4 (Henriksson et al.,
2015). Kristopher Clark (University of Dundee) discussed the
therapeutic potential of targeting the SIKs for the treatment of
chronic inflammatory diseases. Previous work has revealed
that inhibition of the SIKs with the pan-SIK inhibitor HG-9-91-01
elevates the production of anti-inflammatory cytokines, while
suppressing the production of proinflammatory cytokines in
macrophages. Hedescribed theSIKs asmajor targets of the anti-
cancer drugs bosutinib and dasatinib that mediate the effects of
these drugs on the innate immune system (Ozanne et al., 2015).
He proposed to repurpose these therapeutics for the treatment
of chronic inflammatory diseases.
Guy Rutter (Imperial College London) investigated the respec-
tive roles for LKB1 and AMPK in the control of b-cell identity.
In this context, although LKB1 and AMPK signaling only partly
overlap to maintain b cell identity, they act by suppressing the
expression of different subsets of hepatic and neuronal genes
(Kone et al., 2014). BiplabDasgupta (Cincinnati Children’sHospi-
tal Medical Center) presented an example for the differential role
of LKB1 and AMPK in the regulation of cell metabolism. He found
that LKB1 is a key player in the metabolic reprogramming (from
a glycolytic to oxidative metabolism) during differentiation of
Schwann cells, whereas AMPK is largely dispensable. Schwann
cells deficient in LKB1 failed to produce the mitochondrial Krebs
cycle substrate citrate, a precursor to cellular lipids, resulting in
impaired developmental myelination and axonal integrity (Pooya
et al., 2014). In order to identify additional novel targets for AMPK
and its related family members, Reuben Shaw (The Salk Institute
for Biological Studies) presented a strategy employing in vivo
quantitative proteomic analysis through metabolic labeling of
proteins with a heavy stable isotope of nitrogen. Ongoing work
concerns the identification and characterization of phosphopro-
teins in metformin-treated wild-type versus mice lacking LKB1.
TheHerbert Young Investigator Award andPoster Prizes
John Kyriakis (Associate Editor at the Journal of Biological
Chemistry) presented the Herbert Tabor Young InvestigatorCell Metabolism 21, June 2, 2015 ª2015 Elsevier Inc. 803
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bolic regulation in lymphoma.
The organizers David Carling and Benoit Viollet awardedClaire
Speirs (University of Glasgow) and Pablo Hollstein (The Salk
Institute for Biological Studies) prizes for the best poster presen-
tations illustrating the crosstalk between AMPK and JAK-STAT
pathway and the control of cell motility through LKB1-MARK
signaling, respectively.
Concluding Remarks
This conference showcased the advances that have been made
in the understanding of the mechanisms of AMPK regulation and
our current knowledge of new downstream targets and signaling
pathways controlled by AMPK. Given the significance of these
findings and the new questions that they raise, we anticipate
that the next meetings on AMPK and AMPK-related protein
kinases will be equally exciting. Remaining challenges in the
field include the translation of basic research into therapeutic ap-
proaches and the development of therapeutics, such as isoform-
specific small-molecule AMPK activators.
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